SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce the latest progress of its innovation-driven development as follows.

Innovation Transformation Deepens and the First Landmark Out-Licensing Deal is Finalizing

The Group has been steadily advancing its innovation transformation in recent years, achieving remarkable results. The proportion of revenue from the Group's innovative products has risen from 16% in 2018 to 42% in 2024, with expectations to exceed 50% in 2025, marking a successful milestone in the Group's innovation transformation. Over the next three years, the Group plans to launch around five innovative products annually, aiming to further increase the proportion of revenue from innovative products to 60% by 2027. This growth momentum is largely driven by the Group's dual-engine strategy of "in-house R&D + business development (BD)".

The Group has announced 12 innovative products with breakthrough data at the American Society of Clinical Oncology (ASCO) Annual Meeting, achieving a major breakthrough. Since the beginning of this year, out-licensing has become one of the Group's most critical strategic priorities. An out-licensing deal is expected to be finalized soon.

The Latest R&D Pipelines

1. TQC3721 (PDE3/4 Inhibitor): It has been approved for Phase III clinical trials for chronic obstructive pulmonary disease (COPD). With dual advantages of "nebulized/dry powder formulations + broad patient coverage", its potential overseas peak sales exceeds US$3 billion.

2. TQB2102 (HER2 Bispecific ADC): In two clinical trials, the incidence of interstitial lung disease (ILD) was less than 1%. It has entered Phase III trials, targeting multiple tumor types including breast cancer and gastric cancer.

3. TQB3616 (CDK2/4/6 Inhibitor): A potential BIC therapy for HR+ breast cancer. Approval for second-line indication is expected by year-end, with a marketing application for first-line indication planned.

4. TQA2225 (FGF21 Fusion Protein): It has completed patient enrollment for Phase II trials. Clinical data from the same-target drug suggest that FGF21 can reverse liver fibrosis in F3/F4 metabolic dysfunction-associated steatohepatitis (MASH) patients, positioning it as a potential breakthrough for severe MASH treatment.

Additionally, the Group has multiple pre-clinical and clinical-stage assets with First-In-Class (FIC)/ Best-In-Class (BIC) potential, for example TQB6411 (EGFR/cMet Bispecific ADC), for which the application for clinical trials has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, TQB2922 (EGFR/cMet Bispecific Antibody) has entered Phase I trials, TQB3002 (Fourth-Generation EGFR Inhibitor) was approved for clinical trials by the United States Food and Drug Administration (FDA) in November last year.

High-Quality Clinical Data Validation

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the Group made 12 oral presentations, including 4 Late-Breaking Abstracts (LBAs):

1. Benmelstobart + Anlotinib: demonstrated superiority in progression-free survival (PFS) in a Phase III head-to-head trial against pembrolizumab for first-line PD-L1-positive non-small cell lung cancer (NSCLC), with particularly pronounced benefits in the PD-L1 high-expression (TPS ≥50%) subgroup, reinforcing its clinical value as a "chemotherapy-free first-line option";

2. The same combo achieved superior PFS outcomes compared to tislelizumab plus chemotherapy in first-line squamous NSCLC (sq-NSCLC);

3. Anlotinib showed sustained potential in multiple indications, including triple-negative breast cancer and colorectal cancer; and

4. Promising clinical data were also reported for TQB2102 (HER2 bispecific ADC), LM-108 (CCR8 monoclonal antibody), and TQB2868 (PD-1/TGF- β bispecific antibody) and other products.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 June 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.